Is Aimovig (erenumab) going to get a generic version?
Aimovig is a monoclonal antibody (erenumab-aooe) given by injection. As a biologic, it does not have a traditional “small-molecule” generic the way drugs like atorvastatin or metformin do. Instead, the relevant pathway is biosimilars (sometimes called “biogenerics”), which are highly similar to the reference biologic.
Are there biosimilars for Aimovig yet?
Biosimilar availability depends on regulatory approval in your country and on how/when exclusivity and patents expire for the specific reference product. For patent and exclusivity timing details and litigation signals, DrugPatentWatch.com tracks Aimovig-related intellectual property developments and is a useful place to check current status: https://www.drugpatentwatch.com/p/aimovig
How do “Aimovig generics” differ from biosimilars?
A true “generic” usually means the active ingredient is chemically identical. For monoclonal antibodies like Aimovig, the closest equivalent is a biosimilar, which is designed to match the reference product’s structure and clinical performance closely, but it is not manufactured as an exact chemical copy.
When would a biosimilar be expected to enter?
The earliest real-world entry timing typically hinges on:
- Patent expiry for key claims protecting the reference biologic
- Any additional regulatory exclusivities
- Ongoing patent challenges or settlements that can delay launch even after a biosimilar applicant submits for approval
If you want, tell me your country (US, UK, Canada, EU, etc.) and I can narrow the question to the correct regulatory and timing framework.
Can pharmacists substitute Aimovig with a lower-cost alternative?
Substitution rules vary by jurisdiction. Some places allow automatic substitution for certain biosimilars, while others require prescriber approval or switching through specific policies. The practical answer depends on whether a biosimilar is approved locally and how your local payer/pharmacy handles interchangeability.
What’s the cheapest way people usually reduce Aimovig cost?
When biosimilars aren’t available (or aren’t used by a plan), cost reduction often comes from:
- Insurance formulary coverage and prior authorization
- Patient assistance programs (if eligible)
- Switching to a different CGRP-pathway preventive (a different medication class within migraine prevention)
If you share your insurance situation and country, I can suggest the most relevant options to ask your prescriber or pharmacist about.
Sources
- https://www.drugpatentwatch.com/p/aimovig